Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 82

Results For "Post"

1357 News Found

Zydus Wellness' FY23 consolidated net sales up 12.8% at Rs. 2243 Cr
News | May 22, 2023

Zydus Wellness' FY23 consolidated net sales up 12.8% at Rs. 2243 Cr

Glucon-D, Sugar Free, EverYuth Scrub, Peel Off Face Mask and Nycil maintained their leadership positions in their respective categories as on March 2023


Moderna presents Phase 1/2 of MRNA-3927at 2023 ASGCT Meeting
Clinical Trials | May 20, 2023

Moderna presents Phase 1/2 of MRNA-3927at 2023 ASGCT Meeting

First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement


Emcure Pharmaceuticals to launch the750 mg injectable variant of ferric carboxymaltose
News | May 17, 2023

Emcure Pharmaceuticals to launch the750 mg injectable variant of ferric carboxymaltose

Single dose of Ferric Carboxymaltose (FCM) up to 750 mg of iron can be infused in 15 minutes


Briefs: Dr. Reddy's Laboratories and Max Healthcare Institute
News | May 15, 2023

Briefs: Dr. Reddy's Laboratories and Max Healthcare Institute

Dr. Reddy's Laboratories has been issued a Form 483 with four observations


Alembic Q4 FY23 consolidated PAT up at Rs. 48.25 Cr
News | May 13, 2023

Alembic Q4 FY23 consolidated PAT up at Rs. 48.25 Cr

Alembic has reported total income of Rs. 39.15 crores during the period ended March 31, 2023


Cipla reports Q4 FY 23 consolidated PAT at Rs. 525.65 Cr
News | May 13, 2023

Cipla reports Q4 FY 23 consolidated PAT at Rs. 525.65 Cr

Cipla has reported total income of Rs. 5873.93 crores during the period ended March 31, 2023


Bliss GVS Pharma Q4 FY2023 consolidated PAT drops at Rs. 3.34 Cr
News | May 12, 2023

Bliss GVS Pharma Q4 FY2023 consolidated PAT drops at Rs. 3.34 Cr

The company has reported total income of Rs. 187.75 crores during the period ended March 31, 2023


Orchid Pharma Q4 FY23 consolidated PAT up at Rs. 59.13 Cr
News | May 11, 2023

Orchid Pharma Q4 FY23 consolidated PAT up at Rs. 59.13 Cr

The company has reported total income of Rs. 211.62 crores during the period ended March 31, 2023


Formosa Pharmaceuticals and AimMax Therapeutics announce NDA Submission to USFDA for APP13007
Drug Approval | May 08, 2023

Formosa Pharmaceuticals and AimMax Therapeutics announce NDA Submission to USFDA for APP13007

APP13007 is a novel aqueous nanosuspension formulation for the treatment of inflammation and pain following ocular surgery


Hyderabad startup’s Physiotherapy monitoring device ‘Pheezee’ receives USFDA
Medical Device | May 05, 2023

Hyderabad startup’s Physiotherapy monitoring device ‘Pheezee’ receives USFDA

Pheezee is designed to assess musculoskeletal and neuromuscular health.